The Formula That Worked for Decades No Longer Does

You know the playbook. Scale distribution. Increase ad spend. Ship an incremental line extension. Repeat.

For most of the last 30 years, that formula worked. It no longer does. And if you're in R&D or sourcing at a mid-market brand right now, the pressure you're feeling isn't a blip — it's structural.

McKinsey's recent analysis of the private label shift makes the case plainly: the traditional CPG growth model has stopped working, and brands treating this as a temporary squeeze are going to be caught flat-footed.

Key takeaways:

The Numbers Behind the Squeeze

US food sales volume is growing under 1% per year. Food prices are up roughly 30% since 2019. Together, those two facts describe a market where volume has stalled and consumers are exhausted.

The result is predictable: trade-down. Shoppers are moving to private label and smaller pack sizes — not because they've abandoned quality expectations, but because national brands have priced themselves out of the weekly basket.

Large CPG responded by raising prices further. PepsiCo, Hershey, General Mills — all took significant pricing action over the past few years. All lost volume as a result. That's not a coincidence. It's a signal that brand equity alone no longer justifies a price premium when the store brand next to it on the shelf has genuinely improved.

Private Label Isn't What It Used to Be

This is the part that should concern every R&D director at a national brand.

Kroger's Simple Truth Protein line has expanded to more than 80 items. Amazon merged its Fresh and Happy Belly lines into a unified Amazon Grocery brand with over 1,000 SKUs. These aren't generic knockoffs — they're well-formulated, well-packaged products with real nutritional positioning and clean-label credentials.

Retailers have spent the last five years closing the quality gap. They've hired food scientists. They've invested in formulation. They've built supply chains that move faster than the national brand procurement cycle.

The question isn't whether private label quality has improved. It has. The real question is: what does a national or mid-market brand offer that a well-executed store brand doesn't?

For a long time, the answer was trust, familiarity, and distribution. Those advantages are eroding — especially with younger shoppers who have no particular loyalty to brands they didn't grow up with.

The Affordability-Health Tension Is Not Going Away

Here's the uncomfortable part for R&D teams: the two biggest consumer pressures point in opposite directions.

Affordability pressure drives trade-down — cheaper options, smaller packs, fewer premium purchases. Health and ingredient-quality expectations pull the other way: cleaner labels, better protein sources, lower sugar, more transparency.

Incremental innovation doesn't resolve this. A reformulation that adds 2g of fiber to an existing SKU doesn't address either pressure in any meaningful way. It doesn't make the product cheaper. It doesn't make it substantially healthier. It doesn't give a skeptical younger shopper a reason to choose it over a private label alternative that costs less and has a shorter ingredient list.

The brands threading this needle are doing it through genuine product differentiation — not line extensions.

Smaller Brands Are Winning on Speed and Story

McKinsey's analysis highlights a category of smaller, nimble brands outperforming on innovation speed and authentic consumer connection. B.T.R. Nation and Lil Bucks are examples of brands that built real audiences through social-driven storytelling and moved quickly on product development — without the overhead of a large CPG organization.

These brands aren't winning because they have bigger budgets. They're winning because they can make a formulation decision in days, not quarters. They can respond to a consumer trend before a large brand has finished its internal approval process. And they can tell a coherent story about why their ingredients matter — because they actually chose those ingredients deliberately, not because they inherited them from a 1998 formulation.

That speed advantage is real. But it's also fragile. As retailers invest more in their own store brands, smaller brands face the same private label pressure as the nationals — just with fewer resources to respond.

The Underestimated Competitor: Restaurants and Delivery

One competitor that rarely shows up in CPG competitive reviews: the restaurant and delivery channel.

DoorDash and similar platforms have made restaurant-quality meals more accessible and more price-competitive than they used to be. For a consumer deciding between a $12 CPG product and a $14 delivered meal, the calculus has shifted. Convenience is no longer a clear win for packaged goods.

This matters most for snacking, meal kits, and prepared foods — exactly the categories where mid-market CPG brands have been trying to grow.

What McKinsey's Prescription Actually Means for R&D and Sourcing

McKinsey's recommendation is to rethink products and operations, and rebuild relevance with younger, less brand-loyal shoppers. Right diagnosis. But abstract enough to mean almost anything.

For R&D directors and sourcing leads, it translates to a few specific operational realities.

Formulation decisions need to be faster and better-informed. The brands that survive this shift will be the ones that can evaluate a new ingredient across nutrition, cost, sustainability, and supply-chain risk simultaneously — not sequentially, over six months of supplier emails and spreadsheet reconciliation.

Clean, connected data is not a nice-to-have. If your nutrition data lives in one system, your supplier data in another, and your cost data in a spreadsheet someone updates manually, you cannot move at the speed this market requires. Data fragmentation is a competitive disadvantage, not just an operational inconvenience.

Ingredient differentiation is the actual moat. If your formulation looks like the private label version of your product, you don't have a product story. The brands holding share have genuine ingredient differentiation — specific protein sources, functional ingredients with documented benefits, sourcing stories that hold up to scrutiny.

Sourcing risk is now a product risk. A supply disruption that forces a last-minute ingredient substitution can compromise the exact differentiation that justifies your price premium. Monitoring supplier health and having substitution options pre-evaluated isn't just a procurement discipline — it's a product integrity issue.

This is the kind of work that platforms like Journey Foods are built for: connecting ingredient, supplier, nutrition, cost, and sustainability data so R&D and sourcing teams can evaluate options across all those dimensions at once, rather than stitching together answers from five different systems.

The Open Question: What's the Defensible Moat?

Here's the question worth sitting with: if private label quality has genuinely caught up, what remains defensible for large CPG brands?

Brand equity is the obvious answer. But brand equity with younger shoppers is weaker than it was with previous generations, and it erodes faster when the product itself doesn't justify the premium.

Innovation speed is another candidate. But large CPG organizations are structurally slower than smaller brands — and increasingly slower than retailers building out their own private label R&D capabilities.

Some argue the moat is distribution and shelf presence. That's real, but private label occupies that shelf by definition.

The more interesting argument is that the moat is formulation capability and data infrastructure: the ability to identify emerging ingredients before they're mainstream, reformulate quickly in response to supply disruptions, and build products that are genuinely difficult to replicate at private label margins. That requires infrastructure — not just talent.

For smaller brands, the parallel question is whether the speed advantage is sustainable. As retailers hire better food scientists and invest more in their own store brand programs, the gap between a nimble startup and a well-resourced private label operation narrows. What keeps a smaller brand ahead when the retailer can copy the format and undercut the price?

There's no clean answer. But the brands asking that question now — and building the operational capability to respond — are better positioned than the ones still running the old playbook.

Explore how food and CPG teams use connected ingredient and formulation data to make faster decisions at Journeyfoods.io.

FAQs

What is the main reason the traditional CPG growth playbook has stopped working?
Stalled volume growth, sustained price inflation, and a genuine improvement in private label quality have eroded the price premium and brand loyalty the old model depended on. Consumers have more credible alternatives than they did a decade ago.

How has private label quality changed in recent years?
Retailers like Kroger and Amazon have invested significantly in formulation, packaging, and nutritional positioning for their store brands. Kroger's Simple Truth Protein line now spans more than 80 items; Amazon's Amazon Grocery brand exceeds 1,000 SKUs. These are no longer generic alternatives — they're competitive products.

Why are smaller CPG brands outperforming larger ones on innovation?
Smaller brands make formulation and sourcing decisions faster, respond to consumer trends before large organizations complete internal approval cycles, and tell more authentic ingredient stories. The advantage is structural, not just cultural.

What does the affordability-health tension mean for R&D teams?
Consumers simultaneously want lower prices and cleaner, higher-quality ingredients. Incremental innovation — small tweaks to existing formulations — doesn't address either pressure. R&D teams need products with genuine differentiation, not line extensions.

How does supply chain risk connect to product differentiation?
If your product's value proposition depends on specific ingredients, a supply disruption that forces a substitution can undermine the differentiation that justifies your price premium. Proactive supplier monitoring and pre-evaluated substitution options protect product integrity, not just supply continuity.

What does McKinsey recommend for CPG brands facing this shift?
The core prescription is to rethink products and operations and rebuild relevance with younger, less brand-loyal consumers — moving away from incremental innovation and price-led growth toward genuine product differentiation and faster operational decision-making.

What is the defensible moat for CPG brands if private label quality has caught up?
This is genuinely contested. Brand equity still matters but is weaker with younger consumers. Distribution is real but doesn't differentiate from private label. The strongest emerging argument is formulation capability and data infrastructure — the ability to identify, evaluate, and deploy differentiated ingredients faster than competitors can replicate them.